Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-10-09 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that the repurchases comply with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and treasury share transactions. This fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2024-10-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations of compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and treasury share changes. This fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-10-08 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosure of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that the repurchases were made in accordance with exchange rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure about share repurchases and treasury share transactions, fitting the category of Transaction in Own Shares (POS). The length and detail confirm it is the report itself, not just an announcement of a report.
2024-10-07 English
INSIDE INFORMATION - UPDATE ON LEGAL PROCEEDINGS INVOLVING ASC41 AND ASC43F
Legal Proceedings Report Classification · 100% confidence The document is an announcement made by Ascletis Pharma Inc. regarding an update on legal proceedings involving their drug candidates ASC41 and ASC43F. It references a complaint filed with the United States International Trade Commission (ITC) and an initial determination by an Administrative Law Judge. The content focuses on legal matters, the company's disagreement with the determination, and potential next steps. There are no financial statements, earnings data, or management discussion of financial results. The document is clearly an update on ongoing legal proceedings rather than a financial report or other filing type. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is about 4832 characters, which is consistent with a detailed announcement but not a full report like an annual or interim report.
2024-10-07 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 September 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2024. It details movements in authorised/registered share capital, issued shares, share options, and confirms compliance with listing rules. The content focuses on share capital changes and confirmations related to securities issued or treasury shares sold or transferred. There is no financial performance data, earnings information, or management discussion. The document is a regulatory submission related to share capital movements and confirmations under Hong Kong Exchange rules, which fits the category of Regulatory Filings (RNS) as it does not constitute a full financial report or announcement of a report publication but a compliance filing with detailed share capital movement information.
2024-10-03 English
VOLUNTARY ANNOUNCEMENT - GANNEX'S STRATEGIC PARTNER SAGIMET ANNOUNCES RECEIPT OF FDA BREAKTHROUGH THERAPY DESIGNATION FOR ASC40 (DENIFANSTAT) FOR TREATMENT OF BIOPSY-CONFIRMED F2/F3 MASH
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding a strategic partner Sagimet receiving FDA Breakthrough Therapy designation for a drug. It is an announcement of a business development event, not a financial report or regulatory filing. The document is relatively short (3061 characters) and does not contain financial statements, management discussion, or detailed regulatory compliance information. It is not an earnings release, annual report, or any other formal report type. It is also not a notice of voting results, director dealings, or capital changes. The content focuses on a strategic development and FDA designation, which is a business update. Therefore, the best fitting category is Regulatory Filings (RNS) as a general regulatory/business announcement that does not fit other specific categories.
2024-10-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.